Latest Breaking News On - Hape ink potential 1 5b deal to develop eye aav gene therapies - Page 1 : comparemela.com

To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases.

Francois vigneaultToshiki sudoSumitomo pharmaJapan otsuka pharmaceuticals onOsaka research centerOtsuka pharmaceuticalsShape therapeuticsDrug discoveryHape ink potential 1 5b deal to develop eye aav gene therapies